Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia

International Journal of Antimicrobial Agents

Volumn 30, Issue 2, 2007, Pages 162-168

  Benko, Ria ^a   Matuz, Maria ^a   Doro, Peter ^a   Peto, Zoltan ^b   Molnar, Anna ^b   Hajdu, Edit ^b   Nagy, Erzsebet ^b   Gardi, Janos ^b   Soos, Gyongyver ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Critically ill; Levofloxacin; Pharmacodynamics; Pharmacokinetics; Ventilator associated pneumonia

Indexed keywords

LEVOFLOXACIN;

ADULT; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; ERADICATION THERAPY; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CRITICAL ILLNESS; FEMALE; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; PNEUMONIA, VENTILATOR-ASSOCIATED; PROSPECTIVE STUDIES;

EID: 34347267246     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.03.016     Document Type: Article

References (41)

1. Barcenilla F., Gasco E., Rello J., et al. Antibacterial treatment of invasive mechanical ventilation-associated pneumonia. Drugs Aging 18 (2001) 189-200
2. Fish D.N. Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'. Expert Rev Anti Infect Ther 1 (2003) 371-387
3. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
4. Alvarez-Lerma F., Grau S., and Alvarez-Beltran M. Levofloxacin in the treatment of ventilator-associated pneumonia. Clin Microbiol Infect 12 Suppl. 3 (2006) 81-92
5. Shorr A.F., Zadeikis N., Jackson W.L., et al. Levofloxacin for treatment of ventilator-associated pneumonia: a subgroup analysis from a randomized trial. Clin Infect Dis 40 Suppl 2 (2005) S123-S129
6. Pea F., Di Qual E., Cusenza A., Brollo L., Baldassarre M., and Furlanut M. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. Clin Pharmacokinet 42 (2003) 589-598
7. Pea F., Viale P., and Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 44 (2005) 1009-1034
8. Rebuck J.A., Fish D.N., and Abraham E. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy 22 (2002) 1216-1225
9. Sanchez Navarro A., Colino Gandarillas C.I., Alvarez Lerma F., Menacho Y.A., and Dominguez-Gil A. Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients. Clin Pharmacokinet 44 (2005) 627-635
10. Boselli E., Breilh D., Rimmele T., et al. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. Crit Care Med 33 (2005) 104-109
11. Tayab Z.R., Hochhaus G., Kaufmann S., Jager D., and Barth J. Do intensive care patients need an individualized dosing regimen for levofloxacin?. Int J Clin Pharmacol Ther 44 (2006) 262-269
12. Pugin J., Auckenthaler R., Mili N., Janssens J.P., Lew P.D., and Suter P.M. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic 'blind' bronchoalveolar lavage fluid. Am Rev Respir Dis 143 (1991) 1121-1129
13. Liang H., Kays M.B., and Sowinski K.M. Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 772 (2002) 53-63
14. Mouton J.W., Dudley M.N., Cars O., Derendorf H., and Drusano G.L. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 55 (2005) 601-607
15. Preston S.L., Drusano G.L., Berman A.L., et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279 (1998) 125-129
16. Aminimanizani A., Beringer P., and Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet 40 (2001) 169-187
17. Barger A., Fuhst C., and Wiedemann B. Pharmacological indices in antibiotic therapy. J Antimicrob Chemother 52 (2003) 893-898
18. Schentag J.J., Meagher A.K., and Forrest A. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials. Ann Pharmacother 37 (2003) 1478-1488
19. Kiem S., and Schentag J.J. Relationship of minimal inhibitory concentration and bactericidal activity to efficacy of antibiotics for treatment of ventilator-associated pneumonia. Semin Respir Crit Care Med 27 (2006) 51-67
20. Forrest A., Nix D.E., Ballow C.H., Goss T.F., Birmingham M.C., and Schentag J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37 (1993) 1073-1081
21. Madaras-Kelly K.J., Ostergaard B.E., Hovde L.B., and Rotschafer J.C. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother 40 (1996) 627-632
22. Zelenitsky S.A., Harding G.K., Sun S., Ubhi K., and Ariano R.E. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother 52 (2003) 668-674
23. Lister P.D., and Sanders C.C. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 43 (1999) 79-86
24. Lacy M.K., Lu W., Xu X., et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 43 (1999) 672-677
25. Wright D.H., Brown G.H., Peterson M.L., and Rotschafer J.C. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 46 (2000) 669-683
26. Lister P.D., and Sanders C.C. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 47 (2001) 811-818
27. Mattoes H.M., Banevicius M., Li D., et al. Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae. Antimicrob Agents Chemother 45 (2001) 2092-2097
28. Ambrose P.G., Grasela D.M., Grasela T.H., Passarell J., Mayer H.B., and Pierce P.F. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 45 (2001) 2793-2797
29. Lister P.D. Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. Antimicrob Agents Chemother 46 (2002) 69-74
30. Lister P.D. Impact of AUC/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones. J Antimicrob Chemother 51 (2003) 199-202
31. Drusano G.L., Preston S.L., Fowler C., Corrado M., Weisinger B., and Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 189 (2004) 1590-1597
32. Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing. Fifteenth Informational Supplement. M100-S15. Wayne, PA: CLSI; 2005.
33. Le Gall J.R., Lemeshow S., and Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270 (1993) 2957-2963
34. Wise R. Protein binding of beta-lactams: the effects on activity and pharmacology particularly tissue penetration. II. Studies in man. J Antimicrob Chemother 12 (1983) 105-118
35. Bergogne-Berezin E. Clinical role of protein binding of quinolones. Clin Pharmacokinet 41 (2002) 741-750
36. Theuretzbacher U. Tissue concentrations; protein binding. In: 14th International Society of Anti-Infective Pharmacology (ISAP) Educational Workshop, Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents; 1 April 2006; Nice, France. http://www.isap.org/2006/ECCMID-ISAP-Workshop-2006/slides/Theuretzbacher .pdf. [accessed 5 March 2007].
37. Sigma. Mueller-Hinton agar datasheet. http://www.sigmaaldrich.com/sigma/datasheet/m9552dat.pdf [accessed 5 March 2007].
38. Noel G.J., Goodman D.B., Chien S., Solanki B., Padmanabhan M., and Natarajan J. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol 44 (2004) 464-473
39. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 58 Suppl. 2 (1999) 29-36
40. Kiser T.H., Hoody D.W., Obritsch M.D., Wegzyn C.O., Bauling P.C., and Fish D.N. Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. Antimicrob Agents Chemother 50 (2006) 1937-1945
41. European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoints. Basel, Switzerland: EUCAST; 2004. http://www.srga.org/eucastwt/MICTAB/index.html [accessed 5 March 2007].